SCHEMBL6403483

SCHEMBL6403483

Cc1ccc(NCC(c2ccc(-c3ccc(O)cc3)s2)P2(=O)N(C)CCN2C)c(C)n1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 3/20 0.33
HSD17B1 P14061 1/20 0.31
APP P05067 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316425 0.75 KDM4E (0.31)
SCHEMBL6401040 0.74 APP (0.33) HSD17B2HSD17B1APP
SCHEMBL6407329 0.74 ESRRG (0.32) HSD17B2HSD17B1APP
SCHEMBL6278264 0.73 WRN (0.32) HSD17B2HSD17B1APP
SCHEMBL6325408 0.72
SCHEMBL6272802 0.71 HSD17B1 (0.31) HSD17B2HSD17B1APP
SCHEMBL6272796 0.71 WRN (0.31)
SCHEMBL6399807 0.69 ESR1 (0.30) APP
SCHEMBL6402237 0.67 LMNA (0.33)
SCHEMBL6402240 0.67 LMNA (0.34) HSD17B2HSD17B1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels QUATRX PHARMACEUTICALS CO. 2005-06-30 US claimed
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels QUATRX PHARMACEUTICALS CO. 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels APOB, LDLR, LPL HSD17B2 2833/4885HSD17B1 2446/4885APP 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.